- Home
- CTNM
as 05-20-2024 4:00pm EST
$.
+$.
+.%
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 372.2M | IPO Year: | 2024 |
| Target Price: | $28.00 | AVG Volume (30 days): | 127.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.27 - $16.09 | Next Earning Date: | 05-16-2024 |
| Revenue: | $50,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Contineum Therapeutics Inc. Class A Common Stock News
CTNM Breaking Stock News: Dive into CTNM Ticker-Specific Updates for Smart Investing
Business Wire
2 hours ago
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
Business Wire
4 days ago
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
2 months ago